Guggenheim analyst Charles Zhu downgraded Neoleukin Therapeutics to Neutral from Buy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NLTX:
- Neoleukin Therapeutics presents preclinical data on NEO-TRA1 at ASH
- Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
- Neoleukin Therapeutics reports Q3 EPS (24c), consensus (30c)
- Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update